Ok saw the update(see below) and I have a question maybe someone can answer...Mary Haak-Frendscho, Ph.D., board chairman of SF CGEN office is also CEO,of Igenica, Inc. and she is also presenting at the TRI-CON event....so is Igenica a competitor or a potential partner to CGEN..??? Can anyone explain her duality of interests?
Dr.John Hunter, VP, Antibody Research & Development , Compugen Inc., to present at the Molecular Med TRI-CON 2013| Feb 11,2013 - Feb 15,2013
Finding Suitable Targets for Cancer Biologics...also presenting
Mary Haak-Frendscho, Ph.D., CEO,Igenica, Inc.
Considerations for sourcing primary samples
Balancing novelty with known biology
Identifying pathways and signaling systems
Assessing penetrance and abundance of expression
Engaging the patient's immune response
Increasing tumor delivery and penetration
Re: Mary Haak-Frendscho: She still serves as the COB for Compugen Inc (the subsidiary in SF). When she initially took that role, she committed to working full-time for CGEN on a temporary basis to establish the SF operation. Once that work was completed, she stepped back into a traditional advisory Chairperson role, thus allowing her to work full-time for another company while still acting in the best interests of CGEN. I believe this plan was discussed in the 2nd quarter call last year. Dr John Hunter is head of the SF site for daily operations.